| Ms Kristina Gewitsch, FNP-BC | |
|
1317 Roxbury Ct, Murfreesboro, TN 37128-2715 | |
| (615) 642-8149 | |
| Not Available |
| Full Name | Ms Kristina Gewitsch |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 1317 Roxbury Ct, Murfreesboro, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033588462 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163WE0003X | Registered Nurse - Emergency | 177903 (Tennessee) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 2015011090 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Garnet Health Medical Center | Middletown, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Orange Emergency Services Pc | 4880853183 | 23 |
News Archive
Zelos Therapeutics, Inc. has initiated dosing in a seven day clinical study of a nasal spray formulation of ZT-034 (teriparatide) that is being developed in collaboration with development partner Aegis Therapeutics, LLC. Nasal spray ZT-034 is being developed as an alternative to Eli Lilly and Company's Forteo (teriparatide [rDNA origin]) which generated approximately $800M in annual sales in 2009 for the treatment of osteoporosis and is administered by daily injection.
The current standard of care for early-stage breast cancer is breast conserving surgery (lumpectomy) to remove the tumor followed by radiation and hormone therapy to kill any remaining cells.
Foresight Corporation's Chief Technology Officer Ed Hafner testified Thursday, December 10, before the National Committee on Vital and Health Statistics (NCVHS) Subcommittee on Standards, providing insights and recommendations to help the industry prepare for the upcoming transition to the ASC X12 5010 transaction standard and ICD-10 code sets, as mandated by HIPAA.
The most common treatments for cancer are radiation and chemotherapy. However they have side effects and also damage healthy tissues. Moreover, their effectiveness is limited when the cancer has spread through out the body. Researchers at the Niels Bohr Institute are therefore working to develop a gentler treatment that 'tricks' the cancer cells, which would absorb a cytotoxin and therefore be destroyed, while healthy cells would remain unaffected. The results are published in the scientific journal, Scientific Reports.
› Verified 2 days ago
| Entity Name | Anderson Medical Pc Dba Emergency One |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114043411 PECOS PAC ID: 0648161653 Enrollment ID: O20040322000091 |
News Archive
Zelos Therapeutics, Inc. has initiated dosing in a seven day clinical study of a nasal spray formulation of ZT-034 (teriparatide) that is being developed in collaboration with development partner Aegis Therapeutics, LLC. Nasal spray ZT-034 is being developed as an alternative to Eli Lilly and Company's Forteo (teriparatide [rDNA origin]) which generated approximately $800M in annual sales in 2009 for the treatment of osteoporosis and is administered by daily injection.
The current standard of care for early-stage breast cancer is breast conserving surgery (lumpectomy) to remove the tumor followed by radiation and hormone therapy to kill any remaining cells.
Foresight Corporation's Chief Technology Officer Ed Hafner testified Thursday, December 10, before the National Committee on Vital and Health Statistics (NCVHS) Subcommittee on Standards, providing insights and recommendations to help the industry prepare for the upcoming transition to the ASC X12 5010 transaction standard and ICD-10 code sets, as mandated by HIPAA.
The most common treatments for cancer are radiation and chemotherapy. However they have side effects and also damage healthy tissues. Moreover, their effectiveness is limited when the cancer has spread through out the body. Researchers at the Niels Bohr Institute are therefore working to develop a gentler treatment that 'tricks' the cancer cells, which would absorb a cytotoxin and therefore be destroyed, while healthy cells would remain unaffected. The results are published in the scientific journal, Scientific Reports.
› Verified 2 days ago
| Entity Name | Orange Emergency Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043589682 PECOS PAC ID: 4880853183 Enrollment ID: O20120306000546 |
News Archive
Zelos Therapeutics, Inc. has initiated dosing in a seven day clinical study of a nasal spray formulation of ZT-034 (teriparatide) that is being developed in collaboration with development partner Aegis Therapeutics, LLC. Nasal spray ZT-034 is being developed as an alternative to Eli Lilly and Company's Forteo (teriparatide [rDNA origin]) which generated approximately $800M in annual sales in 2009 for the treatment of osteoporosis and is administered by daily injection.
The current standard of care for early-stage breast cancer is breast conserving surgery (lumpectomy) to remove the tumor followed by radiation and hormone therapy to kill any remaining cells.
Foresight Corporation's Chief Technology Officer Ed Hafner testified Thursday, December 10, before the National Committee on Vital and Health Statistics (NCVHS) Subcommittee on Standards, providing insights and recommendations to help the industry prepare for the upcoming transition to the ASC X12 5010 transaction standard and ICD-10 code sets, as mandated by HIPAA.
The most common treatments for cancer are radiation and chemotherapy. However they have side effects and also damage healthy tissues. Moreover, their effectiveness is limited when the cancer has spread through out the body. Researchers at the Niels Bohr Institute are therefore working to develop a gentler treatment that 'tricks' the cancer cells, which would absorb a cytotoxin and therefore be destroyed, while healthy cells would remain unaffected. The results are published in the scientific journal, Scientific Reports.
› Verified 2 days ago
| Entity Name | North Shore Lij Urgent Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679970891 PECOS PAC ID: 6002131778 Enrollment ID: O20150223000060 |
News Archive
Zelos Therapeutics, Inc. has initiated dosing in a seven day clinical study of a nasal spray formulation of ZT-034 (teriparatide) that is being developed in collaboration with development partner Aegis Therapeutics, LLC. Nasal spray ZT-034 is being developed as an alternative to Eli Lilly and Company's Forteo (teriparatide [rDNA origin]) which generated approximately $800M in annual sales in 2009 for the treatment of osteoporosis and is administered by daily injection.
The current standard of care for early-stage breast cancer is breast conserving surgery (lumpectomy) to remove the tumor followed by radiation and hormone therapy to kill any remaining cells.
Foresight Corporation's Chief Technology Officer Ed Hafner testified Thursday, December 10, before the National Committee on Vital and Health Statistics (NCVHS) Subcommittee on Standards, providing insights and recommendations to help the industry prepare for the upcoming transition to the ASC X12 5010 transaction standard and ICD-10 code sets, as mandated by HIPAA.
The most common treatments for cancer are radiation and chemotherapy. However they have side effects and also damage healthy tissues. Moreover, their effectiveness is limited when the cancer has spread through out the body. Researchers at the Niels Bohr Institute are therefore working to develop a gentler treatment that 'tricks' the cancer cells, which would absorb a cytotoxin and therefore be destroyed, while healthy cells would remain unaffected. The results are published in the scientific journal, Scientific Reports.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Kristina Gewitsch, FNP-BC 1317 Roxbury Ct, Murfreesboro, TN 37128-2715 Ph: (615) 642-8149 | Ms Kristina Gewitsch, FNP-BC 1317 Roxbury Ct, Murfreesboro, TN 37128-2715 Ph: (615) 642-8149 |
News Archive
Zelos Therapeutics, Inc. has initiated dosing in a seven day clinical study of a nasal spray formulation of ZT-034 (teriparatide) that is being developed in collaboration with development partner Aegis Therapeutics, LLC. Nasal spray ZT-034 is being developed as an alternative to Eli Lilly and Company's Forteo (teriparatide [rDNA origin]) which generated approximately $800M in annual sales in 2009 for the treatment of osteoporosis and is administered by daily injection.
The current standard of care for early-stage breast cancer is breast conserving surgery (lumpectomy) to remove the tumor followed by radiation and hormone therapy to kill any remaining cells.
Foresight Corporation's Chief Technology Officer Ed Hafner testified Thursday, December 10, before the National Committee on Vital and Health Statistics (NCVHS) Subcommittee on Standards, providing insights and recommendations to help the industry prepare for the upcoming transition to the ASC X12 5010 transaction standard and ICD-10 code sets, as mandated by HIPAA.
The most common treatments for cancer are radiation and chemotherapy. However they have side effects and also damage healthy tissues. Moreover, their effectiveness is limited when the cancer has spread through out the body. Researchers at the Niels Bohr Institute are therefore working to develop a gentler treatment that 'tricks' the cancer cells, which would absorb a cytotoxin and therefore be destroyed, while healthy cells would remain unaffected. The results are published in the scientific journal, Scientific Reports.
› Verified 2 days ago
Lisa A Hill, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 509 E Bell St, Ste 224, Murfreesboro, TN 37130 Phone: 615-848-0488 | |
Heather Lynn Marks, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1272 Garrison Dr, Murfreesboro, TN 37129 Phone: 615-893-4480 | |
Bria J Terrell, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1272 Garrison Dr, Murfreesboro, TN 37129 Phone: 615-867-8000 | |
Mr. Richard Anthony Planzo, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1800 Medical Center Pkwy Ste 200, Murfreesboro, TN 37129 Phone: 158-966-8006 | |
Ms. Casey M Meeks, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1840 Medical Center Pkwy Ste 300, Murfreesboro, TN 37129 Phone: 615-848-0488 Fax: 615-904-9061 | |
Tammy Warren, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3400 Lebanon Rd, Murfreesboro, TN 37129 Phone: 615-867-6000 | |
Myrvienne Jackson, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 514 Brandies Cir Ste A, Murfreesboro, TN 37128 Phone: 615-849-4081 |